EBV (+) GC is a distinct subset identified by The Cancer Genome Atlas (TCGA) Research Network.8 In 2018, Panda A et al. first published that one refractory EBV (+) GC case obtained partial response (PR) after anti-PD-L1 treatment.9 A separate study documented a 100% objective response rate (ORR) in GC patients with EBV positivity who were treated with PD-1 inhibitors.10 Increasing data, including prospective clinical trials from our team, have shown that the ORR to PD-1 inhibitors in EBV (+) GC is ~25%,5,11–13 higher than that in EBV (−) GC. Here, PDCD1 is linked to gastric cancer.